DNA Methylation in Candidate Genes as a Biomarker for Transgenerational Risk of Preeclampsia

Preeclampsia (PE), characterized by global fetal undernutrition due to placental insufficiency, affects over 100,000 women annually in the US. Gene-environment interactions resulting from placental insufficiency during critical developmental windows may explain differential methylation of key genes associated with familial risk of PE. In this study, our goal was to validate methylation status of CpG dinucleotides in loci of genes identified via genome-wide methylation array (Illumina Infinium) in women with and without PE (n=6/group).

DNA Methylation as a Biomarker for Preeclampsia

BACKGROUND: Preeclampsia contributes significantly to pregnancy-associated morbidity and mortality as well as future risk of cardiovascular disease in mother and offspring, and preeclampsia in offspring. The lack of reliable methods for early detection limits the opportunities for prevention, diagnosis, and timely treatment.

Syndicate content